Intervacc (OM:IVACC) - Aktienkurs, Nachrichten und Analyse

IVACC Aktienübersicht

Intervacc AB (publ) entwickelt in Schweden neuartige Veterinärimpfstoffe für Tiere.

IVACC grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 78.7%

Risikoanalyse

Erzielt weniger als 1 Million USD an Einnahmen (SEK10M)

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Hat keine nennenswerte Marktkapitalisierung (SEK241M)

Intervacc AB (publ) Wettbewerber

Alzinova

OM:ALZ

SEK 304.9m

Biovica International

OM:BIOVIC B

SEK 231.7m

AcouSort

OM:ACOU

SEK 218.0m

Saniona

OM:SANION

SEK 485.0m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Intervacc
Historische Aktienkurse
Aktueller Aktienkurs	SEK 3.56
52-Wochen-Hoch	SEK 10.46
52-Wochen-Tief	SEK 2.90
Beta	0.63
11 Monat Veränderung	-13.17%
3 Monate Veränderung	9.88%
1 Jahr Veränderung	0.85%
33 Jahre Veränderung	-94.55%
5 Jahre Veränderung	-77.47%
Veränderung seit IPO	-53.77%

Aktuelle Nachrichten und Updates

Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?

Jun 08

Recent updates

Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation

Dec 15

It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers

Jun 01

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

May 17

Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling

Feb 28

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

Feb 01

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Jan 06

Is Intervacc AB (publ)'s (STO:IVACC) Shareholder Ownership Skewed Towards Insiders?

Dec 10

Aktionärsrenditen

	IVACC	SE Biotechs	SE Markt
7D	-2.2%	0.8%	1.6%
1Y	0.8%	31.4%	25.5%

Rendite im Vergleich zur Industrie: IVACC unter dem Niveau der Branche Swedish Biotechs , die im vergangenen Jahr eine Rendite von 6.6% erzielte.

Rendite vs. Markt: IVACC hinter dem Markt Swedish zurück, der im vergangenen Jahr eine Rendite von 13.9 erzielte.

Preisvolatilität

Is IVACC's price volatile compared to industry and market?
IVACC volatility
IVACC Average Weekly Movement	7.6%
Biotechs Industry Average Movement	9.0%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	11.6%
10% least volatile stocks in SE Market	3.2%

Stabiler Aktienkurs: IVACC hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: IVACCDie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1983	15	Jonas Sohlman	www.intervacc.se

Intervacc AB (publ) entwickelt in Schweden neuartige Veterinärimpfstoffe für Tiere. Die Produktpipeline des Unternehmens umfasst Stangvac, einen Impfstoff gegen Pferdewürmer für Pferde, INV274, Antigene für einen Impfstoff gegen Strep. suis zur Behandlung von Ferkeln, und INV412, einen Mehrkomponenten-Impfstoff zum Schutz gegen mehrere Mastitis verursachende Bakterien zur Behandlung von Kühen.

Intervacc AB (publ)'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Intervacc im Vergleich zum Marktanteil des Unternehmens?
IVACC grundlegende Statistiken
Marktanteil	SEK 269.62m
Gewinn(TTM)	-SEK 102.66m
Umsatz(TTM)	SEK 9.78m

27.6x

Kurs-Umsatz-Verhältnis

-2.6x

Kurs-Gewinn-Verhältnis

Ist IVACC zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
IVACC Gewinn- und Verlustrechnung (TTM)
Einnahmen	SEK 9.78m
Kosten der Einnahmen	SEK 24.17m
Bruttogewinn	-SEK 14.39m
Sonstige Ausgaben	SEK 88.26m
Umsatz	-SEK 102.66m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

Nov 14, 2024

Gewinn per Aktie (EPS)	-1.36
Bruttomarge	-147.20%
Nettogewinnspanne	-1,049.76%
Schulden/Eigenkapital-Verhältnis	0.06%

Wie hat sich IVACC auf lange Sicht entwickelt?

Historische Performance und Vergleiche

IVACC Aktienübersicht

Belohnungen

Risikoanalyse

Intervacc AB (publ) Wettbewerber

OM:ALZ

SEK 304.9m

OM:BIOVIC B

SEK 231.7m

OM:ACOU

SEK 218.0m

OM:SANION

SEK 485.0m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023)

Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Recent updates

Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023)

Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Intervacc AB (publ) to Report Q1, 2024 Results on May 23, 2024

Intervacc AB (publ) Announces Changes in the Nomination Committee

No independent directors

Intervacc AB (publ) Announces Executive Changes

New major risk - Share price stability

Third quarter 2023 earnings released: kr0.78 loss per share (vs kr0.29 loss in 3Q 2022)

Intervacc AB (publ) Announces Composition of Nomination Committee

We're Keeping An Eye On Intervacc's (STO:IVACC) Cash Burn Rate

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr0.31 loss in 2Q 2022)

Intervacc AB (publ) Announces Executive Changes

Intervacc AB (publ) Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova

Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million.

Intervacc AB (Publ) Approves the Election of Boel Sundvall as Board Member

The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months

Veterinary Medicines Directorate (VMD) Extends the Shelf Life for Intervacc AB (publ)'s Strangvac, a Vaccine Against Equine Strangvac, to 33 Months

First quarter 2023 earnings released: kr0.35 loss per share (vs kr0.21 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

We Think Intervacc (STO:IVACC) Needs To Drive Business Growth Carefully

Full year 2022 earnings released: kr1.28 loss per share (vs kr0.59 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Intervacc AB (publ) to Report Fiscal Year 2022 Results on Apr 06, 2023

Intervacc AB (Publ) Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Intervacc AB (Publ) Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands Released

We're Not Very Worried About Intervacc's (STO:IVACC) Cash Burn Rate

Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2021)

Intervacc AB (Publ) Announces That Strangvac Is Now Available for Sale in the Uk

Intervacc AB (Publ) Elects Michela De Carli as Board Member At the Annual General Meeting Held on June 14, 2022

Intervacc Announces Strangvac, A Vaccine Against Equine Strangles, Available for Sale in Denmark

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Intervacc AB (publ) Announces Initiation of a Proof-Of-Concept Study to Measure the Effectiveness of a Vaccine to Protect Dairy Cows Against Mastitis

We're Not Worried About Intervacc's (STO:IVACC) Cash Burn

Ntervacc AB (Publ) Announces Positive Results from A Proof-Of-Concept Study to Develop A Vaccine Against Streptococcus Suis Infection in Pigs

Full year 2021 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Intervacc AB (publ), Annual General Meeting, Jun 14, 2022

Intervacc Applies for A Permit for Sale and Distribution of Strangvac in the U.S

Intervacc Applies for Supplementary Protection Certificates for Strangvac in Key European Markets

Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation

Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 2Q 2020)

Intervacc Receives Confirmation of a Positive Outcome for Strangvac, a Vaccine against Equine Strangles, from the VMD in the UK

Intervacc AB Receives Positive CVMP Opinion for Strangvac, A Vaccine Against Equine Strangles, in the EU

Independent Director Newton Aguiar has left the company

It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers

First quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 1Q 2020)

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

Independent Director recently sold kr29m worth of stock

Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling

New 90-day high: kr76.60

Erträge & Einnahmen